On March 24, 2026, Bayer’s stock experienced a brief decline following a significant divestment by Inclusive Capital Partners. The move by activist investor Jeff Ubben triggered a short-lived sell-off, reflecting shifting sentiment toward the German pharmaceutical and agricultural giant.
Key transaction details and market impact:
-
Size of the Sale: Inclusive Capital offloaded approximately 8.5 million shares, representing a 0.9% stake in the company. The transaction was valued at nearly $380 million.
-
Stock Performance: The news initially triggered a 3% drop in Bayer’s share price. While the stock partially rebounded by the end of the day, it remained lower than its levels from the previous week.
-
A Complicated History: Jeff Ubben first took a stake in Bayer in 2023 and played a pivotal role in the ousting of former CEO Werner Baumann in favor of Bill Anderson. Ubben has previously advocated for a breakup of Bayer’s business units, though such a structural change has not yet materialized.
-
Pressure on Leadership: Current CEO Bill Anderson recently delivered a 2026 outlook that set targets lower than market expectations. He described the company as being in a “comprehensive turnaround” phase, noting that while progress is visible, the work to unleash Bayer’s full potential is not yet complete.
The exit of an investor who was instrumental in reshaping Bayer’s leadership raises questions about market confidence in the pace of the company’s strategic recovery.